# MondoTwin — Comprehensive Company & Platform Information

## What is MondoTwin?

MondoTwin is an AI-powered platform and ETH Zurich startup that transforms unexploited academic research into ready-to-license rare disease therapies. The company connects the world of science with the world of patients by bridging the gap between academic researchers with promising rare disease discoveries and pharmaceutical/biotech companies seeking de-risked, clinical-stage assets.

## The Problem MondoTwin Solves

- Over 7,000 rare diseases exist worldwide, affecting approximately 300 million people globally (5% of the world population).
- 30 million patients in the USA and 36 million in Europe suffer from rare diseases.
- The vast majority of rare diseases have no approved treatment.
- Promising academic research often never reaches patients because researchers lack the resources, IP strategy, regulatory knowledge, and industry connections to commercialize their work.
- Pharmaceutical companies struggle to find and evaluate early-stage rare disease assets efficiently.

## How MondoTwin Works

### For Researchers
Researchers and institutions (universities, hospitals, research institutes, technology transfer offices, principal investigators, early-stage biotech) working on clinical-stage rare-disease research register it with MondoTwin, starting with a short non-confidential summary. MondoTwin then:
- Assesses and positions the research
- Builds the development case (regulatory, clinical, IP strategy, financial modelling), prepared with the researcher
- Introduces it to development partners (pharma, biotech, foundations, investors, public funders)
- Keeps the researcher at the centre as the scientific lead
There are no fees for researchers or institutions.

### For Development Partners
MondoTwin works with pharma, biotech, foundations, investors, and public funders searching for clinical-stage rare-disease programs:
- Programs from MondoTwin's own pipeline, available under confidentiality
- Targeted searches on mandate, across the world's clinical evidence and the research hosted on MondoTwin
- Assets constructed in the partner's name and supported to signature
Mandates are scoped individually. Contact: https://www.mondotwin.com/pharma

### The Technology Platform
MondoTwin's AI-powered platform:
- Transforms raw academic research into structured, licensable Medical Product Candidates (MPCs)
- Provides automated analysis and regulatory mapping
- Facilitates pharma matchmaking between researchers and companies
- Uses AI to evaluate research potential and commercial viability

## Company Background

- Founded: 2024
- Origin: ETH Zurich startup
- Co-Founder & CTO: Francesco Cavalli
- Status: Filed first patent applications, expanding to the United States
- Structure: MondoTwin is a brand of SHRARE Technology AG (Basel, Switzerland; CHE-340.780.334)
- Platform: https://platform.mondotwin.com/

## Key Facts & Statistics

- 7,000+ rare diseases worldwide
- ~300M people affected globally
- 5% of global population affected
- 30M patients in the USA
- 36M patients in Europe
- 650M new rare cancer cases per year in Europe
- 100% of pediatric cancers are classified as rare

## Rare Cancer Focus

MondoTwin researchers contribute to accelerating the development of rare cancer therapies. Rare cancers are defined as fewer than 40,000 cases per year per cancer type.

## Contact & Links

- Website: https://www.mondotwin.com
- Platform: https://platform.mondotwin.com
- Contact: https://www.mondotwin.com/about#contact